Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782819 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL29366771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10901771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2857061 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL28699910 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL6266491 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10414846 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL353797 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL356145 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| Heptanoic Acid Chloromethyl Ester SCHEMBL697729 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409466-A1 | HIGH DENSITY WASHABLE MINING GROUTING REINFORCEMENT MATERIAL AND PREPARATION METHOD THEREOF | CCRI (Beijing) New Material Technology Co., Ltd. (CN) | 2024-12-12 | — | — | US | claimed |
| CN-114395320-B | Chemical anti-sagging exposed single-component polyurethane waterproof coating and preparation method thereof | 唐山东方雨虹防水技术有限责任公司 | 2023-02-17 | — | — | CN | claimed |
| CN-114395320-A | Chemical anti-sagging exposed single-component polyurethane waterproof coating and preparation method thereof | 唐山东方雨虹防水技术有限责任公司 | 2022-04-26 | — | — | CN | claimed |
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570605-B2 | Indole compounds, and preparation methods, and uses thereof | SHENZHEN 01 LIFE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20250282812-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4512805-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-4501926-A1 | N-SUBSTITUTED QUINOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Vigonvita Life Sciences Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| US-5243043-A | Cephalosporin antibiotics and bactericides | ROUSSEL UCLAF (FR) | 1993-09-07 | — | — | US | disclosed |
| US-4992431-A | Bactericides or antibiotics | ROUSSELUCLAF (FR) | 1991-02-12 | — | — | US | disclosed |
| US-4727151-A | CLEAVED TO DRUGS IN VIVO BY CHEMICAL OR ENZYMATIC HYDROLYSIS | INTERX RESEARCH CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| US-4699925-A | ANTIINFLAMMATORY AGENTS, ANALGESICS AND-OR ANTIPYRETICS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1987-10-13 | — | — | US | disclosed |
| EP-0103265-B1 | BIPHENYLYLPROPIONIC ACID DERIVATIVE, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1986-12-03 | — | — | EP | disclosed |
| EP-0103265-A2 | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4267326-A | AS ANTITUMOR AGENTS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1981-05-12 | — | — | US | disclosed |
| US-4160099-A | Labile, non-heterocyclic quaternary ammonium salt/esters as transient derivatives | INTERX RESEARCH CORPORATION | 1979-07-03 | — | — | US | disclosed |
| US-4061722-A | Selected quaternary ammonium salts of pilocarpine useful in reducing intraocular pressure in warm-blooded animals | INTERX RESEARCH CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | DGKA 2991/4885PAM 1063/4885TSHR 399/4885 |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | DGKA 2015/4885PAM 2776/4885TSHR 2778/4885 |
| US-20250282812-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SAMHD1, PNP, NUDT1 | DGKA 3635/4885PAM 531/4885TSHR 4461/4885 |
| US-12570605-B2 | Indole compounds, and preparation methods, and uses thereof | IDO2, IDO1, TPH2 | DGKA 2440/4885PAM 3927/4885TSHR 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.